The MAD1L1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal knockout cell population targeting the MAD1L1 gene in the Raji B lymphocyte cell line. This knockout model ablates the function of MAD1L1, a critical component of the mitotic spindle assembly checkpoint (SAC), providing a powerful tool for investigating chromosome segregation fidelity and genomic instability. The polyclonal population preserves heterogeneous editing events, offering robust representation of loss-of-function phenotypes without clonal selection bias, suitable for a broad range of functional genomic studies.
Raji cells are a well-characterized Epstein?CBarr virus (EBV)-positive human B lymphocyte line derived from a Burkitt lymphoma patient. As a model of B-cell malignancy, Raji cells exhibit robust proliferation and are extensively used in immunological and cancer research. Their lymphoid origin and EBV-driven transformation make them particularly relevant for studying lymphomagenesis, B-cell receptor signaling, and the impact of chromosomal instability on tumor development. The MAD1L1 knockout in this background enables dissection of mitotic checkpoint dysregulation specifically within the context of B-cell lymphoma biology.
MAD1L1 functions as an essential scaffold at unattached kinetochores, where it is recruited by upstream kinases including BUB1, Aurora B, and MPS1. It directly interacts with MAD2L1, catalyzing the conversion of MAD2 into a closed conformation that binds and inhibits CDC20, a co-activator of the anaphase-promoting complex/cyclosome (APC/C). This inhibition prevents premature degradation of Securin and Cyclin B, thereby delaying anaphase onset until all chromosomes achieve proper bipolar attachment. Additional regulatory inputs from PLK1 and BUBR1 further modulate MAD1L1 localization and stability, integrating multiple signals to ensure accurate chromosome segregation.
In the Raji lymphoma background, MAD1L1 knockout disrupts the SAC, leading to accelerated mitotic progression, chromosome missegregation, and consequent aneuploidy. This recapitulates the chromosomal instability frequently observed in aggressive B-cell malignancies and provides a defined genetic model to study the consequences of checkpoint failure. The EBV-positive nature of Raji cells adds an additional layer of relevance, as viral oncoproteins may interact with mitotic pathways. Researchers can employ this model to explore how checkpoint dysfunction contributes to lymphomagenesis, drug resistance, and sensitivity to microtubule poisons such as paclitaxel and nocodazole.
This knockout cell product is ideally suited for applications including quantification of aneuploidy via chromosome spread analysis, assessment of mitotic timing through live-cell imaging, and flow cytometry-based cell cycle profiling. It also enables drug sensitivity screens to evaluate the potency of microtubule-targeting agents and other mitotic inhibitors in a checkpoint-deficient context. Western blotting and immunofluorescence can validate MAD1L1 loss and examine downstream targets such as MAD2 and CDC20. For further details or to discuss custom projects, please contact Ascent Research.
